Literature DB >> 9126959

A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes.

C C Winter1, E O Long.   

Abstract

To examine the structural basis for the specific recognition of the MHC class I allotypes HLA-Cw*0401 and HLA-Cw*0304 by the killer cell inhibitory receptors (KIR) cl42 and cl43, respectively, mutant KIR-Ig fusion proteins were tested by direct binding to cells transfected with single HLA-C alleles. The putative loop region at position 44-46 of KIR contained amino acids that were necessary for the discrimination between HLA-Cw*0401 and HLA-Cw*0304. Surprisingly, exchanging the methionine at position 44 in cl42 with the lysine at position 44 in cl43 was sufficient to switch the specificity of cl42 from HLA-Cw*0401 to HLA-Cw*0304, and vice versa. Thus, a single amino acid in the first Ig domain of these KIR determines their ability to discriminate between the two groups of HLA-C allotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126959

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  The human natural killer cell immune synapse.

Authors:  D M Davis; I Chiu; M Fassett; G B Cohen; O Mandelboim; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.

Authors:  Hojjatollah Nozad Charoudeh; Laurent Schmied; Asensio Gonzalez; Grzegorz Terszowski; Karol Czaja; Karin Schmitter; Laura Infanti; Andreas Buser; Martin Stern
Journal:  Immunogenetics       Date:  2012-07-07       Impact factor: 2.846

3.  Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Authors:  Hugo G Hilton; Luca Vago; Anastazia M Older Aguilar; Achim K Moesta; Thorsten Graef; Laurent Abi-Rached; Paul J Norman; Lisbeth A Guethlein; Katharina Fleischhauer; Peter Parham
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

4.  Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.

Authors:  Hugo G Hilton; Lisbeth A Guethlein; Ana Goyos; Neda Nemat-Gorgani; David A Bushnell; Paul J Norman; Peter Parham
Journal:  J Immunol       Date:  2015-08-26       Impact factor: 5.422

5.  Two Orangutan Species Have Evolved Different KIR Alleles and Haplotypes.

Authors:  Lisbeth A Guethlein; Paul J Norman; Corinne M C Heijmans; Natasja G de Groot; Hugo G Hilton; Farbod Babrzadeh; Laurent Abi-Rached; Ronald E Bontrop; Peter Parham
Journal:  J Immunol       Date:  2017-03-06       Impact factor: 5.422

Review 6.  Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules.

Authors:  Peter Parham; Paul J Norman; Laurent Abi-Rached; Lisbeth A Guethlein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-03-19       Impact factor: 6.237

7.  Presence of more activating KIR genes is associated with Hashimoto's thyroiditis.

Authors:  Elham Ashouri; Mohammad Hossein Dabbaghmanesh; Gholamhossein Ranjbar Omrani
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

8.  Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11.

Authors:  Jingxian Liu; Ziwei Xiao; Hui Ling Ko; Meixin Shen; Ee Chee Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors.

Authors:  M Valés-Gómez; H T Reyburn; R A Erskine; J Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 10.  Co-evolution of MHC class I and variable NK cell receptors in placental mammals.

Authors:  Lisbeth A Guethlein; Paul J Norman; Hugo G Hilton; Peter Parham
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.